The Week in Review: China Life Science to Grow 22% Per Year Through 2013

IMS Health predicts China’s drug market will see a 22% CAGR during 2010-2113, compared to 4%-6% worldwide; fifteen early stage China life science entrepreneurs were selected as Finalists in the SEED Competition; Chi-Med may IPO its drug development arm, Hutchison MediPharma, possibly on Nasdaq; WuXi PharmaTech (药明康德) struck a two-way pre-clinical services deal with a J&J subsidiary; aTyr Pharma received a second 18-month grant to fund research at its Hong Kong subsidiary; Sanofi-Aventis is seeking additional partnerships in China; Asymchem Labs will build another manufacturing plant in TEDA; Mindray Medical (迈瑞医疗国际有限公司), released very positive financial results and raised $150 million in new cash; Biostar Pharma expects a 35% increase in 2010 revenues; and Kalen Biomedical found a China distribution partner for its research products. More details… Stock Symbols: (NYSE: RX) (AIM: HCM) (NYSE: WX) (NYSE: JNJ) (NYSE: SNY) (NYSE: MR) (OTCBB: BSPM)